



1 **Equality considerations**

2 [The equality and health inequalities assessment for the guideline update \[hyperlink](#)  
3 [to the update EIA\]](#) lists equality and health inequality issues identified and how they  
4 have been addressed, and explains why any populations were excluded from the  
5 scope.

6 **2 Activities, services or aspects of care covered by**  
7 **the guideline update**

8 We will look at the evidence and consider making new recommendations, or  
9 updating existing recommendations, on methenamine hippurate as an alternative to  
10 antibiotic prophylaxis for treating recurrent UTI. For more information, see the [2022](#)  
11 [surveillance review decision](#).

12 For all other areas of the guideline:

- 13 • There will be no evidence review.  
14 • We will retain the existing recommendations but we may revise them to ensure  
15 consistency and reflect current NICE style.

16 **3 Draft review questions**

17 We have identified the following draft review question:

18 **What is the clinical and cost effectiveness of methenamine hippurate when**  
19 **compared to antibiotics in the prevention of recurrent UTIs for adults and**  
20 **children?**

21 Note that guideline recommendations for medicines will normally fall within licensed  
22 indications; exceptionally, and only if clearly supported by evidence, use outside a  
23 licensed indication may be recommended. The guideline will assume that prescribers  
24 will use a medicine's summary of product characteristics to inform decisions made  
25 with individual patients.

## 1 **4 Economic aspects**

2 We will take economic aspects into account when making recommendations. We will  
3 review the economic evidence and carry out economic analyses, using NHS  
4 perspective, as appropriate.

## 5 **5 NICE quality standards that may be affected by this** 6 **guideline update**

- 7 • [Urinary tract infections in adults](#) (2015, updated 2023) NICE quality standard  
8 QS90
- 9 • [Urinary tract infection in children and young people](#) (2013, updated 2022) NICE  
10 quality standard QS36

## 11 **6 Further information**

12 NICE guidelines cover health and care in England. Decisions on how they apply in  
13 other UK countries are made by ministers in the [Welsh Government](#), [Scottish](#)  
14 [Government](#) and [Northern Ireland Executive](#).

The guideline update is expected to be published in November 2024.

To follow the progress of the update, see the [guideline in development page](#).

Our website has information about [how NICE guidelines are developed](#).

15

16 © NICE 2024. All rights reserved. Subject to [Notice of rights](#).